Antihipertansif ilaçların kullanımı ile ilişkili yan etkiler: güncel literatürler eşliğinde gözden geçirme

Yüksek kan basıncı olarak da adlandırılan hipertansiyon kan basıncının kronik olarak yüksek olduğu tıbbi durumdur. Hipertansiyon dünya çapında en önemli kardiyovasküler risk faktörlerinden biridir. Antihipertansif ilaçlar hipertansiyon tedavisinde kullanılan bir grup ilaçlardır. Antihipertansif ilaçların baş dönmesi, ayak bileği ödemi, baş ağrısı, yorgunluk, göğüs ağrısı ve öksürük gibi yan etkileri mevcuttur. Hipertansiyon tanısı ile antihipertansif ilaç başlanan hastaların yaklaşık %35’i ilk 6 ay içerisinde ilaçlarını bırakmaktadır ve bunun en önemli sebebi ilaç yan etkileri ve hasta memnuniyetsizliğidir. Bu derlemede antihipertansif ilaçların yan etkilerinin sıklığı, ciddiyeti ve önlenmesi için gerekli çabalar üzerinde durulmuştur.

Anahtar Kelimeler:

Antihipertansif ilaçlar, yan etki, hipertansiyon tedavisi

Adverse reactions associated with the use of antihypertensive drugs: review in the light of current literature

Hypertension, also referred to as high blood pressure, is a medical condition in which the blood pressure is chronically elevated. Hypertension is one of the most important cardiovascular risk factors all around the world. Antihypertensives are a class of drugs that are used in treatment of hypertension. Antihypertensive drugs have several adverse effects including dizziness, ankle swelling, headache, fatigue, chest discomfort and cough. About 35% of hypertensive patients discontinue their medication within six months, and the reason for discontinuation relates to adverse effects and patient dissatisfaction. This review focus on the frequency and severity of the adverse effects of antihypertensive drugs, and attempts made to prevent.

Keywords:

Adverse effects, antihypertensive drugs, hypertension treatment,

PDF

___

1. Mancia G, Fagard R, Narkiewicz K, Redon J et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013 Jul;34:2159-219.
2. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014 Feb 5;311:507-20.
3. Vasan RS, Beiser A, Seshadri S, Larson M.G, Kannel WB, D’Agostino RB. Residual life-time risk for developing hypertension in middle-aged women and men: The framingham Heart study, JAMA 2002;287:1003-10.
4. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336:1114-7.
5. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10;358:1547-59.
6. Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008 Jan 1;148:16-29.
7. Franse LV, Pahor M, Di Bari M et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the elderly program. hypertension. 2000 May;35:1025-30.
8. Joshi VD, Dahake AP, Suthar AP. Adverse Effects Associated with the Use of Antihypertensive Drugs: An Overview. Int.J. PharmTech Res 2010;2:10-3.
9. Olowofela AO, Isah AO. A profile of adverse effects of antihypertensive medicines in a tertiary care clinic in Nigeria. Ann Afr Med 2017 Jul-Sep;16:114-9.
10. Sirker A1, Missouris CG, MacGregor GA.Dihydropyridine calcium channel blockers and peripheral side effects. J Hum Hypertens 2001 Oct;15:745-6.
11. Ward DJ, Ward JW, Griffo W, Rochwarge A. Intravenous calcium for fecal impaction secondary to verapamil. N Engl J Med. 1982 Dec 30;307:1709-10.
12. McHale NG, Allen JM.The effect of external Ca2+ concentration on the contractility of bovine mesenteric lymphatics. Microvasc Res. 1983 Sep;26:182-92.
13. Lins R, Haerden Y, de Vries C. Replacement of amlodipine and lercanidipine by barnidipine: tolerability and effectiveness in a real-life study. High Blood Press Cardiovasc Prev 2017 Mar;24:29-36.
14. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996 May 23;334:1349-55.
15. Wikstrand J, Wedel H, Castagno D, McMurray JJ. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. J Intern Med 2014 Feb;275:134-43.
16. Davidson C, Thadani U, Singleton W, Taylor SH. Comparison of antihypertensive activity of beta-blocking drugs during chronic treatment. Br Med J 1976 Jul 3;2:7-9.
17. Giugliano D, Acampora R, Marfella R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997 Jun 15;126:955-9.
18. Shamon SD, Perez MI. Blood pressure-lowering efficacy of reserpine for primary hypertension. Cochrane Database Syst Rev 2016 Dec 21;12:CD007655.